Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by pelabooston Sep 30, 2023 12:06pm
303 Views
Post# 35663260

Adlai Nortye

Adlai Nortye@Noteable.

I was looking through the AN website and it went down; not sure why. Anyway I did notice they have mentioned PDAC in relation to pelareorep under Science & Pipeline. My point being they have not erased ONCY from their website and presumably will run a Phase 3 mBC trial without a CPI. It is intended for Chinese patients. CPIs are very expensive and that is possibly one of the reasons why PanCAN will also try with and without a CPI.

I agree with your sentiments on opacity et al.  It has been a tortuous journey.
I did add a small amount yesterday, and as a retiree I do not have the loose readies of many here; so I do think we are gathering steam. Perhaps the poster on SW can put up Rubeus Hagrid again; that gave  me a good laugh and has now been included as number four on the ONCY humor list.

Cheers



<< Previous
Bullboard Posts
Next >>